We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

57 hedge funds and large institutions have $375M invested in Monte Rosa Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

10% more funds holding

Funds holding: 52 → 57 (+5)

2.79% less ownership

Funds ownership: 85.88% → 83.09% (-2.8%)

33% less capital invested

Capital invested by funds: $560M → $375M (-$185M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
57
Holders Change
+5
Holders Change %
+9.62%
% of All Funds
0.96%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
12
Increased
19
Reduced
15
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$3.29M
2
BlackRock
BlackRock
New York
+$1.85M
3
UOC
UBS O'Connor
Illinois
+$1.02M
4
State Street
State Street
Massachusetts
+$817K
5
Citadel Advisors
Citadel Advisors
Florida
+$730K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.86M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$7.43M
3
CC
Casdin Capital
New York
-$4.52M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$1.14M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$74.5M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$60.1M -$7.86M -782,004 -11%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$50.8M -$1.02M -101,788 -2%
BlackRock
4
BlackRock
New York
$32M +$1.85M +184,177 +6%
ACA
5
Avoro Capital Advisors
New York
$32M +$1.02K +102 +0%
CAM
6
Cormorant Asset Management
Massachusetts
$28.9M -$85.2K -8,482 -0.3%
Vanguard Group
7
Vanguard Group
Pennsylvania
$21.9M -$7.43M -739,866 -25%
ACM
8
Aisling Capital Management
New York
$14.2M – – –
AI
9
Alphabet Inc
California
$14.2M – – –
RI
10
RTW Investments
New York
$11.7M – – –
CC
11
Casdin Capital
New York
$4.94M -$4.52M -450,000 -47%
State Street
12
State Street
Massachusetts
$4.36M +$817K +81,296 +22%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$3.65M +$204K +20,328 +6%
WP
14
Woodline Partners
California
$3.64M +$3.29M +327,908 +682%
Northern Trust
15
Northern Trust
Illinois
$2.16M +$40.5K +4,027 +2%
TD Asset Management
16
TD Asset Management
Ontario, Canada
$1.36M – – –
Morgan Stanley
17
Morgan Stanley
New York
$1.35M +$49.9K +4,970 +4%
N
18
Nuveen
North Carolina
$1.3M +$712K +70,891 +111%
Bank of America
19
Bank of America
North Carolina
$1.22M -$215K -21,434 -15%
Allianz Asset Management
20
Allianz Asset Management
Germany
$1.18M +$294K +29,253 +32%
Citadel Advisors
21
Citadel Advisors
Florida
$1.16M +$730K +72,642 +154%
Charles Schwab
22
Charles Schwab
California
$1.12M -$92.1K -9,166 -7%
Manulife (Manufacturers Life Insurance)
23
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.02M +$117K +11,688 +13%
UOC
24
UBS O'Connor
Illinois
$983K +$1.02M +101,647 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$679K -$41.3K -4,111 -6%
1
2 3

GLUE Hedge Fund Activity: Q2 2022 in Review

57 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q2 2022, worth a combined $375M — down 33% from $560M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new GLUE positions and 6 closed out — a net gain of 6 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was Woodline Partners, adding an estimated $3.29M. The largest seller was Fidelity Investments, cutting an estimated $7.86M.

  • 57 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q2 2022, up from 52 in Q1 2022.
  • Funds reported $375M of Monte Rosa Therapeutics stock for Q2 2022, down 33% quarter-over-quarter.
  • 12 funds opened new Monte Rosa Therapeutics positions in Q2 2022 and 6 closed out, a net change of +6 holders.
  • The largest Monte Rosa Therapeutics buyer in Q2 2022 was Woodline Partners, an estimated $3.29M added.
  • The largest Monte Rosa Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $7.86M sold.

Based on aggregated 13F filings for Q2 2022.